Change over period
From:
To:
Zoom:
- 3M
- 6M
- YTD
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Acumen Pharmaceuticals Inc
NASDAQ ABOS
Data sourced from
and
and
Download Data
Acumen Pharmaceuticals Inc Price to Book Ratio (P/B) on June 03, 2024: 0.63
Acumen Pharmaceuticals Inc Price to Book Ratio (P/B) is 0.63 on June 03, 2024, a -44.40% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.
-
Acumen Pharmaceuticals Inc 52-week high Price to Book Ratio (P/B) is 2.36 on July 17, 2023, which is 274.50% above the current Price to Book Ratio (P/B).
-
Acumen Pharmaceuticals Inc 52-week low Price to Book Ratio (P/B) is 0.00 on March 18, 2024, which is -99.85% below the current Price to Book Ratio (P/B).
-
Acumen Pharmaceuticals Inc average Price to Book Ratio (P/B) for the last 52 weeks is 0.89.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ABOS
| CEO | Mr. Daniel J. O'Connell M.B.A. |
| IPO Date | July 1, 2021 |
| Location | United States |
| Headquarters | 427 Park Street, Charlottesville, VA, United States, 22902 |
| Employees | 51 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Key trends
Similar companies
Day One Biopharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email